Cancer Res Treat.  2004 Apr;36(2):121-127.

Impact of the New AJCC Staging System and Adjuvant Treatment in Rectal Cancer

• Lee SA
• Kwon HC
• Park MA
• Jung CK
• Kim SH
• Park KJ
• Choi HJ
• Lee HS
• Roh MS
• Kim JS
• Kim HJ

Abstract

PURPOSE
The combination of chemoradiation and fluorouracil based chemotherapy has been the standard adjuvant treatment for colorectal cancer patients. The aim of this study was to evaluate treatment outcome of patients classified by the new AJCC staging system and to compare treatment outcome of oral doxifluridine and the standard Mayo Clinic regimen after chemoradiation in advanced rectal cancer patients. MATERIALS AND METHODS: One hundred nine patients underwent curative surgical resection and chemoradiation followed by chemotherapy. 45 Gy pelvic irradiation was given to the entire pelvis and the boost radiation with 50.4 to 54 Gy, and simultaneously 5-fluorouracil (5-FU) 375 mg/m2/day was given on day 1~3 and 26~28. After the completion of chemoradiation, patients were given either 6 cycles of the Mayo Clinic regimen (5-FU 425 mg/m2 plus leucovorin 20 mg/m2 intravenous bolus infusion on day 1~5, every 4 weeks) or oral doxifluridine (600 mg/m2/day) for 1 year. RESULTS: The median follow-up duration was 30 months. Among 102 evaluable patients, 38 patients (37.3%) relapsed: the locoregional recurrence in 10 patients (9.8%) and systemic relapse in 28 patients (27.5%). The systemic relapse rate was 15.6% in the stage IIA, 25.0% in the stage IIIB, and 59.1% in the stage IIIC (p=0.048). The 5-year disease-free survival (DFS) rate was significantly higher in the IIA and IIIA patients than the IIIB and IIIC patients (72% and 100% vs 48.1% and 11.2%, respectively. p<0.001). The 5-year overall survival (OS) rate was also significantly different between in the IIA/IIIA patients and the IIIB/IIIC (67.3%/100% vs 48.4%/22.3%. p<0.001). However, the difference in DFS or OS between the oral doxifluridine group and the Mayo Clinic regimen group was not significant. Cox regression multivariate analyses showed that the new AJCC stage and tumor differentiation were significant independent prognostic factors in DFS and OS. CONCLUSION: These results support that the new AJCC staging system is superior to Dukes' staging system in the prognostic stratification. Regarding DFS and OS, oral doxifluridine is comparable to the standard Mayo Clinic regimen in rectal cancer patients when combined with postoperative chemoradiation. Stage IIIC patients should be selected for aggressive therapy as they have a dismal prognosis.

Keyword

Rectal neoplasm; Adjuvant Treatment; Chemotherapy; Chemoradiation

MeSH Terms

Colorectal Neoplasms
Disease-Free Survival
Drug Therapy
Fluorouracil
Follow-Up Studies
Humans
Leucovorin
Multivariate Analysis
Pelvis
Prognosis
Rectal Neoplasms*
Recurrence
Treatment Outcome
Fluorouracil
Leucovorin

Figure

• 

  Fig. 1 Overall survival according to the AJCC stage.

• 

  Fig. 2 Overall survival according to the adjuvant chemotherapy.

Reference

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin. 2001; 51:15–36. PMID: 11577478.

2. Bae JM, Won YJ, Jung KW, Park JG. Annual report of the Korea central cancer registry program 2000: based data from 131 hospitals. Cancer Res Treat. 2002; 34:77–83.

3. Krook JE, Moertel CG, Gunderson LL, Wieand HS, Collins RT, Beart RW, Kubista TP, Poon MA, Meyers WC, Mailliard JA. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med. 1991; 324:709–715. PMID: 1997835.

4. Colorectal Cancer Collaborative Group. Adjuvant radiotherapy for rectal cancer: A systematic overview of 8,507 patients from 22 randomised trials. Lancet. 2001; 358:1291–1304. PMID: 11684209.

5. O'Connell MJ, Martenson JA, Wieand HS, Krook JE, Macdonald JS, Haller DG, Mayer RJ, Gunderson LL, Rich TA. Improving adjuvant therapy for rectal cancer by combining protracted-infusion 5-FU with radiation therapy after curative surgery. N Engl J Med. 1994; 331:502–507. PMID: 8041415.

6. Neri B, Gemelli MT, Pantalone D, Pernice ML, Agostino I, Scatizzi M, Siliani GM, Bartolini P, Andreoli F. Results of leucovorin and doxifluridine oral regimen in the treatment of metastatic colorectal caner. Anticancer Drugs. 1998; 9:599–602. PMID: 9773803.

7. Merkel S, Mansmann U, Papadopoulos T, Wittekind C, Hohenberger W, Hermanek P. The prognostic inhomogeneity of colorectal carcinomas Stage III: a proposal for subdivision of Stage III. Cancer. 2001; 92:2754–2759. PMID: 11753948.

8. American Joint Committee on Cancer. AJCC cancer staging manual. 2002. 6th ed. New York: Springer-Verlag;p. 113–123.

9. National Institutes of Health Consensus Conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA. 1990; 264:1444–1450. PMID: 2202842.

10. Fisher B, Wolmark N, Rockette H, Redmond C, Deutsch M, Wickerham DL, Fisher ER, Caplan R, Jones J, Lerner H. Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01. J Natl Cancer Inst. 1988; 80:21–29. PMID: 3276900.

11. Tepper JE, O'Connell M, Niedzwiecki D, Hollis DR, Benson AB III, Cummings B, Gunderson LL, Macdonald JS, Martenson JA, Mayer RJ. Adjuvant therapy in rectal cancer: Analysis of stage, sex, and local control?final report of intergroup 0114. J Clin Oncol. 2002; 20:1744–1750. PMID: 11919230.

12. International multicentre pooled analysis of colon cancer trials (IMPACT) investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet. 1995; 345:939–944. PMID: 7715291.

13. Meta-analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol. 1998; 16:301–308. PMID: 9440757.

14. Liu G, Franssen E, Fitch MI, Warner E. Patient preference for oral versus intravenous palliative chemotherapy. J Clin Oncol. 1997; 15:110–115. PMID: 8996131.

15. Bollag W, Hartmann HR. Tumor inhibitory effects of a new fluorouracil derivative: 5'-deoxy-5-fluorouridine. Eur J Cancer. 1980; 16:427–432. PMID: 6447071.

16. Kono A, Hara Y, Suga S, Karube Y, Matsushima Y, Ishitsuka H. Activation of 5'-deoxy-5-fluorouridine by thymidine phosphorylase in human tumors. Chem Pharm Bull. 1983; 31:175–178. PMID: 6221809.

17. Kim NK, Min JS, Park JK, Yun SH, Sung JS, Jung HC, Roh JK. Intravenous 5-FU versus oral doxifluridine as preoperative concurrent chemoradiation for locally advanced rectal cancer: Prospective randomized trials. Jpn J Clin Oncol. 2001; 31:25–29. PMID: 11256837.

18. Armstroung RD, Cadman E. 5'-Deoxy-5-fluorouridine selective toxicity for human tumor cells compared to human bone marrow. Cancer Res. 1983; 43:2525–2528. PMID: 6221792.

19. Tang R, Wang JY, Chen JS, Chang-Chien CR, Tang S, Lin SE, You YT, Hsu KC, Ho YS, Fan HA. Survival impact of lymph node metastasis in TNM stage III carcinoma of the colon and rectum. J Am Coll Surg. 1995; 180:705–712. PMID: 7773484.

20. Greene FL, Stewart AK, Norton HJ. A new TNM staging strategy for node-positive (stage III) colon cancer: An analysis of 50,042 patients. Ann Surg. 2002; 236:416–421. PMID: 12368669.

21. Greene FL, Stewart AK, Norton HJ. A new TNM staging strategy for node-positive (stage III) rectal cancer: An analysis of 5,988 patients. Proc Am Soc Clin Oncol. 2003; 22:251.